The Committee For Medicinal Products For Human Use Of The European Medicines Agency Has Adopted Negative Opinion On Approval Of Eisai/Biogen's Lecanemab As Treatment For Early Alzheimer's Disease, Eisai Said It Will Seek Re-Examination Of The Opinion
The Committee For Medicinal Products For Human Use Of The European Medicines Agency Has Adopted Negative Opinion On Approval Of Eisai/Biogen's Lecanemab As Treatment For Early Alzheimer's Disease, Eisai Said It Will Seek Re-Examination Of The Opinion
欧洲药品管理局药品人用药品委员会对爱萨伊/渤健公司的来开美单抗用于治疗早期阿尔茨海默病作出负面意见。爱萨伊表示将寻求重新审查意见。
and work with the relevant authorities to ensure this treatment is available for eligible people living with early AD in the European Union (EU) as soon as possible.
并且与有关当局合作，确保这种治疗尽快适用于早期阿尔茨海默病的符合条件的居住在欧盟(EU)的人。